New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export RADX’s income statement to Excel — free account
Radiopharm Theranostics Limited - Sponsored ADR
RADXRadiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
0.63
0.04
−5.97%
After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.
Follow RADX
Alert me
Radiopharm Theranostics Limited - Sponsored ADR (RADX) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LEXX Lexaria Bioscience Corp. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| HIND Vyome Holdings, Inc. compare | n/m |
| BIVI BioVie Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.1× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 21.7× |
| Market median | 16.6× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)